Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report issued to clients and investors on Friday. The firm set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Stock Performance

Shares of BCLI stock opened at $0.34 on Friday. The stock’s fifty day moving average is $0.45 and its two-hundred day moving average is $0.42. The firm has a market capitalization of $24.00 million, a P/E ratio of -1.07 and a beta of 0.37. Brainstorm Cell Therapeutics has a fifty-two week low of $0.13 and a fifty-two week high of $2.12.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. On average, equities analysts forecast that Brainstorm Cell Therapeutics will post -0.28 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC bought a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the first quarter, according to its most recent disclosure with the SEC. The firm bought 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics as of its most recent SEC filing. 14.33% of the stock is owned by institutional investors and hedge funds.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.